The Food and Drug Administration (FDA) has approved Khindivi ™ (hydrocortisone) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.

Eton Pharmaceuticals (ETON) stock gains as the FDA approved Khindivi its oral hydrocortisone solution for children with adrenocortical insufficiency. Read more here.

Eton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and ...

Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) saw a 3.3% boost in premarket trading after the company announced U.S. Food ...